A randomized controlled trial aims to develop evidence-based treatment practices for primary ciliary dyskinesia, a rare respiratory disorder. Azithromycin may offer a potential maintenance prophylactic therapy for PCD patients, improving pulmonary exacerbation rates and quality of life.
The Bestcilia project is launching an international patient registry for primary ciliary dyskinesia (PCD), a rare respiratory disease. The registry aims to collect prospective data on clinical presentation, diagnosis, and treatment outcomes, ultimately improving therapeutic guidelines and quality of life for PCD sufferers.
Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder affecting the respiratory and other systems, with limited data due to small patient populations. The BESTCILIA project aims to improve screening and treatment through clinical trials, standardized diagnostic testing, and patient registries.